- Home
- MTR vs RLMD Comparison
MTR vs RLMD Comparison
Compare MTR & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTR
- RLMD
- Stock Information
- Founded
- MTR 1979
- RLMD 2004
- Country
- MTR United States
- RLMD United States
- Employees
- MTR N/A
- RLMD N/A
- Industry
- MTR Oil & Gas Production
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- MTR Energy
- RLMD Health Care
- Exchange
- MTR Nasdaq
- RLMD Nasdaq
- Market Cap
- MTR 11.2M
- RLMD 11.5M
- IPO Year
- MTR N/A
- RLMD N/A
- Fundamental
- Price
- MTR $6.75
- RLMD $0.37
- Analyst Decision
- MTR
- RLMD Hold
- Analyst Count
- MTR 0
- RLMD 4
- Target Price
- MTR N/A
- RLMD $4.25
- AVG Volume (30 Days)
- MTR 9.5K
- RLMD 942.1K
- Earning Date
- MTR 01-01-0001
- RLMD 03-18-2025
- Dividend Yield
- MTR 3.12%
- RLMD N/A
- EPS Growth
- MTR N/A
- RLMD N/A
- EPS
- MTR 0.35
- RLMD N/A
- Revenue
- MTR $966,169.00
- RLMD N/A
- Revenue This Year
- MTR N/A
- RLMD N/A
- Revenue Next Year
- MTR N/A
- RLMD N/A
- P/E Ratio
- MTR $19.33
- RLMD N/A
- Revenue Growth
- MTR N/A
- RLMD N/A
- 52 Week Low
- MTR $5.60
- RLMD $0.34
- 52 Week High
- MTR $11.99
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- MTR 58.94
- RLMD 25.62
- Support Level
- MTR $6.35
- RLMD $0.36
- Resistance Level
- MTR $6.91
- RLMD $0.49
- Average True Range (ATR)
- MTR 0.30
- RLMD 0.06
- MACD
- MTR 0.09
- RLMD 0.08
- Stochastic Oscillator
- MTR 86.93
- RLMD 10.06
About MTR Mesa Royalty Trust
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.